<DOC>
	<DOCNO>NCT01200264</DOCNO>
	<brief_summary>This Phase II , open label , investigator-initiated study do Duke University Medical Center treat adult patient ( age 18-80 ) chronic plaque psoriasis fail Biologic Therapy Apremilast 30 mg BID 24 week . At time enrollment , patient must receive biologic therapy without achieve response `` almost clear '' `` clear '' accord PGA respond 75 % reduction PASI score . Once deem eligible , subject return baseline visit receive Apremilast therapy instruction . Subjects treat week 0,4,8,12,16,20 24 ; subject evaluate 28 day last dose Apremilast safety efficacy .</brief_summary>
	<brief_title>Apremilast Chronic Plaque Psoriasis ( CPP ) Patients Who Have Failed One Course Biologic Therapy</brief_title>
	<detailed_description>Data Analysis Data analyze report subject complete follow-up phase study . All subsequent data collect analyzed report follow-up clinical report . Data &amp; Safety Monitoring Dr. Murray follow laboratory value adverse event trial . In addition , Celgene provide study monitor , regular interval , review data . All data report Celgene .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Apremilast</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Subjects 1880 yr diagnose moderatetosevere chronic plaque psoriasis PGA 3 great require systemic therapy Must receive biologic therapy CPP achieve PGA 'almost clear ' 'clear ' Must meet lab criterion per Pg 2021 protocol All subject must follow contraceptive measure describe protocol , Pg 21 . Abnormal Chest xray Significant abnormality ECG Positive HIV Ab , Hepatitis B &amp; C Subjects erythrodermic , pustular guttate psoriasis ineligible Serious local infection systemic infection , tuberculosis within 3 mo first dose apremilast</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2010</verification_date>
</DOC>